Robert W. Robey

TL;DR: Evidence is presented indicating that it is time to revisit the investigation into the role of ABC transporters in efficient drug delivery in various cancer types and at the blood–brain barrier, and push forward their clinical application as biomarkers and as targets in combination therapies in order to improve anticancer drug efficiency.

TL;DR: High levels of expression in the S1-M1-80 cells and in the human breast cancer subline, MCF-7 AdVp3000, are consistent with the identification of a new ATP binding cassette transporter, which is overexpressed in mitoxantrone-resistant cells.

TL;DR: The maximum tolerated dose (MTD) of depsipeptide given on a day-1 and -5 schedule every 21 days was defined and biological assays showed that the serum levels achieved could cause the characteristic cell cycle effects of this agent when serum was added to PC3 cells in culture, as well as increased histone acetylation in patient-derived peripheral blood mononuclear cells.

TL;DR: It is suggested that amino acid 482 has a crucial role in MXR/BCRP/ABCP function and that mutation of a single amino acid residue significantly changes substrate specificity, thus altering the drug resistance phenotype.

TL;DR: Research into the transporter's role in cancer drug resistance and its development as a therapeutic target in cancer has lagged but emerging studies in pharmacology and toxicology assessing polymorphic variants in man, in combination with murine knockout models have confirmed its dynamic role.